Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
MDS 2025 | Honolulu, HI
Oct 5 - 9, 2025
Poster
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy ParticipantsMDS 2025 | Honolulu, HI
Oct 5 - 9, 2025
Poster
First Clinical Trials of ARV-102, a PROTAC LRRK2 Degrader: Characterization of Pathway Engagement in Healthy Volunteers and Patients With Parkinson’s DiseaseISSX 2025 | Chicago, IL
Sep 21 - 24, 2025
Poster
Absorption, Metabolism, Excretion, and Pharmacokinetics of [14C] Vepdegestrant in Healthy Adult ParticipantsACCP 2025 | Phoenix, AZ
Sep 14 - 16, 2025
Poster
A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult ParticipantsSOHO 2025 | Houston, TX
Sep 3 - 6, 2025
Poster
Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin LymphomaSOHO 2025 | Houston, TX
Sep 3 - 6, 2025
Poster
ARV-393, a PROTAC BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma ModelsSOHO 2025 | Houston, TX
Sep 3 - 6, 2025
Poster
ARV-393, a PROTAC BCL6 Degrader, in Preclinical Models of Diffuse Large B-cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular LymphomaICML 2025 | Lugano, Switzerland
Jun 17 - 21, 2025
Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma ModelsEHA 2025 | Milan, Italy
Jun 12 - 15, 2025